According to an abstract to be presented at an upcoming conference, researchers from Harvard Medical School found that by adding the drug Zytiga to hormone therapy prior to surgery for men with locally advanced, aggressive prostate cancer, they could completely or nearly completely eradicate the disease in a third of patients in a recent trial.
Typically, locally advanced prostate cancer means high levels of prostate-specific antigen, an aggressive disease that has spread throughout the prostate, and a rather poor prognosis.
This Phase II trial involved 58 men who were given Zytiga along with Lupron (a hormone that stops testosterone production in the testes) for either three months or six months prior to undergoing surgery.
Preliminary results, released ahead of the American Society of Clinical Oncology (ASCO) meeting in Chicago in June demonstrated that among the 29 men who received the combination for six months, in three of the men, doctors could find no evidence of the cancer, and in another seven the disease was almost entirely eradicated.
Currently Zytiga is approved to treat advanced prostate cancer in patients who have already undergone chemotherapy.
Source: ASCO
The information provided on CancerTreatment.net is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational purposes and does not constitute the practice of medicine. We encourage all visitors to see a licensed physician or nutritionist if they have any concerns regarding health issues related to diet, personal image and any other topics discussed on this site. Neither the owners or employees of CancerTreatment.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.
